Viridian Therapeutics reported second-quarter 2026 results and significant milestones. Lumvoa (veligrotug-vvze) was approved by the FDA for thyroid eye disease on June 26, 2026, ahead of its target PDUFA date, and was immediately launched in the U.S. Elegrobart remains on track for a planned BLA submission in the first quarter of 2027, while FcRn and TSHR programs are expected to meet 2026 development milestones. The company also completed a May 2026 convertible debt and equity financing with gross proceeds of $394 million.
For the three months ended June 30, 2026, Viridian generated $284 thousand in total revenues and incurred $126,552 thousand of operating expenses, resulting in a net loss of $127,119 thousand, compared with $100,735 thousand a year earlier. Cash, cash equivalents, and marketable securities were $981,530 thousand as of June 30, 2026, supporting total assets of $1,097,233 thousand, liabilities of $435,136 thousand, and stockholders’ equity of $662,097 thousand.
Viridian Therapeutics director-associated funds received a new stock option grant linked to board service. Investment vehicles managed by Fairmount Funds Management LLC were granted an option covering 32,341 shares of Viridian common stock at an exercise price of $18.48 per share. The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if Christopher W. Cain continues serving on Viridian’s Board of Directors. The option expires on July 1, 2036. Under Cain’s arrangement with Fairmount, any net cash or stock from the option must be turned over to the adviser for the benefit of the Fairmount funds, and Cain disclaims beneficial ownership of both the option and the underlying shares.
Viridian Therapeutics director Jeffrey Robert Ajer received a grant of stock options for 32,341 shares of common stock at an exercise price of $18.48 per share. These options were awarded as compensation and give him the right to buy shares in the future at that fixed price. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, if he continues serving on the board until that time. After this grant, he holds stock options covering 32,341 underlying shares directly.
Viridian Therapeutics director Jennifer K. Moses received a grant of stock options covering 32,341 shares of common stock. The options have an exercise price of $18.48 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market purchase.
The option vests in full on the earlier of July 1, 2027 or the company’s 2027 annual stockholder meeting, as long as she continues serving on the board. After this grant, she holds 32,341 stock options directly according to this filing.
Viridian Therapeutics director Sarah Gheuens received a grant of stock options as part of her board compensation. She was awarded options for 32,341 shares of common stock with an exercise price of $18.48 per share, expiring on July 1, 2036. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, assuming she continues to serve on the board. After this grant, she holds options for 32,341 underlying shares directly.
Viridian Therapeutics director-associated funds received a new stock option grant. An option over 32,341 shares of Viridian common stock was granted at an exercise price of $18.48 per share and expires on July 1, 2036.
The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual stockholder meeting, contingent on Tomas Kiselak continuing to serve on the board. Under an arrangement with Fairmount Funds Management LLC, the option and any related value are for Fairmount-managed investment vehicles, and Kiselak disclaims beneficial ownership.
Viridian Therapeutics director Arlene Morris received a grant of 32,341 stock options. These options give her the right to buy an equal number of Viridian common shares at an exercise price of $18.48 per share and expire on July 1, 2036.
The option vests in full on the earlier of July 1, 2027 or Viridian’s 2027 annual meeting of stockholders, as long as she continues serving on the company’s Board of Directors. After this grant, she holds 32,341 derivative securities directly.
Viridian Therapeutics announced that the FDA has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED) regardless of disease activity or duration. Lumvoa is described as the first TED treatment with labeling that includes data for both active and chronic disease.
The approval is based on the pivotal phase 3 THRIVE (active TED) and THRIVE-2 (chronic TED) trials, which met primary and all secondary endpoints, showing rapid and durable improvements in key signs and symptoms by week 15. Patients received a 12-week course of five intravenous infusions given every three weeks.
Viridian plans to launch Lumvoa immediately and has established the ViridianCares™ support program to help with access, insurance, and financial assistance. The label highlights safety considerations including infusion reactions, hyperglycemia in 12% of patients, potential inflammatory bowel disease exacerbation, and possible severe hearing impairment, as well as common adverse events such as muscle spasms and headache.
Viridian Therapeutics, Inc. Schedule 13G reporting beneficial ownership by Paradigm-related entities and an affiliated fund. The filing shows Paradigm BioCapital Advisors (and related reporting persons) beneficially own 5,633,788 shares (5.1%) and Paradigm BioCapital International Fund Ltd. beneficially owns 4,942,532 shares (4.5%), with these figures stated as of June 18, 2026. The filing bases percentages on 110,427,682 shares outstanding as of May 11, 2026.
The Schedule 13G is a passive ownership disclosure identifying voting and dispositive powers for each reporting person and includes a joint filing agreement. The filing disclaims ownership beyond the shares each reporting person directly beneficially owns.
Viridian Therapeutics held its 2026 Annual Meeting of Stockholders, where holders of common stock as of the April 7, 2026 record date could vote. As of that date, 103,071,889 shares of common stock were issued and outstanding.
Stockholders elected Class II directors Tomas Kiselak and Jennifer K. Moses to serve until the 2029 annual meeting. Kiselak received 72,363,500 votes for and 14,475,646 withheld, while Moses received 86,378,842 for and 460,304 withheld, with 6,733,104 broker non-votes for each.
Stockholders ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 92,866,008 votes for. They also approved, on an advisory basis, executive compensation and indicated a preference to hold the advisory say-on-pay vote every year, which the board has adopted.